PharmGen Science Statistics

Total Valuation

PharmGen Science has a market cap or net worth of KRW 76.45 billion. The enterprise value is 80.84 billion.

Market Cap	76.45B
Enterprise Value	80.84B

Important Dates

The next estimated earnings date is Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

PharmGen Science has 18.14 million shares outstanding. The number of shares has decreased by -1.35% in one year.

Current Share Class	n/a
Shares Outstanding	18.14M
Shares Change (YoY)	-1.35%
Shares Change (QoQ)	+4.67%
Owned by Insiders (%)	11.76%
Owned by Institutions (%)	1.20%
Float	15.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.44
PB Ratio	0.33
P/TBV Ratio	0.33
P/FCF Ratio	30.90
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.48, with an EV/FCF ratio of 32.67.

EV / Earnings	-65.44
EV / Sales	0.47
EV / EBITDA	6.48
EV / EBIT	10.32
EV / FCF	32.67

Financial Position

The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.17.

Current Ratio	1.62
Quick Ratio	1.15
Debt / Equity	0.17
Debt / EBITDA	2.20
Debt / FCF	15.54
Interest Coverage	3.00

Financial Efficiency

Return on equity (ROE) is -0.55% and return on invested capital (ROIC) is 2.96%.

Return on Equity (ROE)	-0.55%
Return on Assets (ROA)	2.35%
Return on Capital (ROIC)	2.96%
Revenue Per Employee	683.46M
Profits Per Employee	-4.86M
Employee Count	254
Asset Turnover	0.51
Inventory Turnover	2.47

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.98% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-29.98%
50-Day Moving Average	4,638.80
200-Day Moving Average	5,160.20
Relative Strength Index (RSI)	37.53
Average Volume (20 Days)	40,349

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmGen Science had revenue of KRW 173.60 billion and -1.24 billion in losses. Loss per share was -68.22.

Revenue	173.60B
Gross Profit	107.15B
Operating Income	12.80B
Pretax Income	-743.28M
Net Income	-1.24B
EBITDA	17.44B
EBIT	12.80B
Loss Per Share	-68.22

Full Income Statement

Balance Sheet

The company has 34.03 billion in cash and 38.44 billion in debt, giving a net cash position of -4.41 billion or -243.15 per share.

Cash & Cash Equivalents	34.03B
Total Debt	38.44B
Net Cash	-4.41B
Net Cash Per Share	-243.15
Equity (Book Value)	230.30B
Book Value Per Share	12,698.69
Working Capital	39.57B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.34 billion and capital expenditures -868.86 million, giving a free cash flow of 2.47 billion.

Operating Cash Flow	3.34B
Capital Expenditures	-868.86M
Free Cash Flow	2.47B
FCF Per Share	136.42

Full Cash Flow Statement

Margins

Gross margin is 61.72%, with operating and profit margins of 7.37% and -0.71%.

Gross Margin	61.72%
Operating Margin	7.37%
Pretax Margin	-0.43%
Profit Margin	-0.71%
EBITDA Margin	10.05%
EBIT Margin	7.37%
FCF Margin	1.43%

Dividends & Yields

PharmGen Science does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.35%
Shareholder Yield	1.35%
Earnings Yield	-1.62%
FCF Yield	3.24%

Stock Splits

The last stock split was on November 17, 2014. It was a reverse split with a ratio of 0.1.

Last Split Date	Nov 17, 2014
Split Type	Reverse
Split Ratio	0.1

Scores

PharmGen Science has an Altman Z-Score of 1.87. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.87
Piotroski F-Score	n/a